Statera rises as FDA lifts clinical hold on its radiation sickness therapy

Statera Biopharma

01/12/2021 13:48

** Shares of drug developer Statera Biopharma Inc  STAB.O 
up ~6% at $3.13 premarket
    ** Co says U.S. FDA has lifted the clinical hold placed on
its lead product candidate, Entolimod, for treating acute
radiation syndrome (ARS)
    ** ARS is an illness caused by a large dose of radiation
often received over a short period of time
    ** FDA acknowledged that STAB satisfactorily addressed
historical regulatory matters  urn:newsml:reuters.com:*:nGNXDk4C2
    ** Entolimod is also being investigated for other
indications, including immunotherapy for cancer
    ** Co also looking to establish a development program in
Oncology and Hematology, with plans to start the first study of
Entolimod in this new area of focus in 2022
    ** Up to Tuesday's close, stock had fallen 14.78% YTD  

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))